After Vertex announced 4-week efficacy and 12-week safety data from two TripleRx Phase 3 trials of VX-659 plus Symdeko, Piper Jaffray analyst Edward Tenthoff said VX-659 achieved “unprecedented” four-week mean absolute improvement in ppFEV1 in both patient populations studied. He anticipates Vertex will file an NDA on the best TripleRx regimen in mid 2019 and currently sees the first TripleRx reaching the market in 2020. Tenthoff keeps an Overweight rating and $217 price target on Vertex shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.